| Gene Symbol |
PLK3
|
| Entrez Gene |
1263
|
| Alt Symbol |
CNK, FNK, PRK
|
| Species |
Human
|
| Gene Type |
protein-coding
|
| Description |
polo-like kinase 3
|
| Other Description |
FGF-inducible kinase|PLK-3|cytokine-inducible kinase|cytokine-inducible serine/threonine-protein kinase|proliferation-related kinase|serine/threonine-protein kinase PLK3
|
| Swissprots |
Q9H4B4 Q5JR99 Q15767 Q96CV1
|
| Accessions |
AAU88146 EAX07021 Q9H4B4 AA421212 AB209875 BAD93112 AJ293866 CAC10659 BC004135 BC004198 BC013899 AAH13899 BC013960 EU832631 ACE87722 EU832706 ACE87038 U56998 AAC50637 XR_246234 XR_946541 NM_004073 NP_004064
|
| Function |
Serine/threonine-protein kinase involved in cell cycle regulation, response to stress and Golgi disassembly. Polo-like kinases act by binding and phosphorylating proteins are that already phosphorylated on a specific motif recognized by the POLO box domains. Phosphorylates ATF2, BCL2L1, CDC25A, CDC25C, CHEK2, HIF1A, JUN, p53/TP53, p73/TP73, PTEN, TOP2A and VRK1. Involved in cell cycle regulation: required for entry into S phase and cytokinesis. Phosphorylates BCL2L1, leading to regulate the G2 checkpoint and progression to cytokinesis during mitosis. Plays a key role in response to stress: rapidly activated upon stress stimulation, such as ionizing radiation, reactive oxygen species (ROS), hyperosmotic stress, UV irradiation and hypoxia. Involved in DNA damage response and G1/S transition checkpoint by phosphorylating CDC25A, p53/TP53 and p73/TP73. Phosphorylates p53/TP53 in response to reactive oxygen species (ROS), thereby promoting p53/TP53-mediated apoptosis. Phosphorylates CHEK2 i
|
| Subcellular Location |
Cytoplasm. Nucleus. Nucleus, nucleolus. Golgi apparatus. Cytoplasm, cytoskeleton, microtubule organizing center, centrosome. Note=Translocates to the nucleus upon cisplatin treatment. Localizes to the Golgi apparatus during interphase. According to a report, PLK3 localizes only in the nucleolus and not in the centrosome, or in any other location in the cytoplasm (PubMed:17264206). The discrepancies in results may be explained by the PLK3 antibody specificity, by cell line- specific expression or post-translational modifications. {ECO:0000269|PubMed:17264206}.
|
| Tissue Specificity |
Transcripts are highly detected in placenta, lung, followed by skeletal muscle, heart, pancreas, ovaries and kidney and weakly detected in liver and brain. May have a short half-live. In cells of hematopoietic origin, strongly and exclusively detected in terminally differentiated macrophages. Transcript expression appears to be down-regulated in primary lung tumor.
|
| Top Pathways |
Tuberculosis
|
